schliessen

Filtern

 

Bibliotheken

Cover Image

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

Objectives: Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD. Design: A cohort study including 6843 HIV-positive persons with at le... Full description

Journal Title: AIDS (London) 2010, Vol.24 (11), p.1667-1678
Main Author: Mocroft, Amanda
Other Authors: Kirk, Ole , Reiss, Peter , de Wit, Stephane , Sedlacek, Dalibor , Beniowski, Marek , Gatell, Jose , Phillips, Anew N , Ledergerber, Bruno , Lundgren, Jens D
Format: Electronic Article Electronic Article
Language: English
Subjects:
610 Medicine & health
Adenine
Adenine - adverse effects
Adenine - analogs & derivatives
Adult
AIDS/HIV
Anti
Anti-HIV Agents - adverse effects
Atazanavir Sulfate
Biological and medical sciences
Chronic
Clinic for Infectious Diseases
Disease Progression
Epidemiologic Methods
Female
Glomerular Filtration Rate
Glomerular Filtration Rate - drug effects
Glomerulonephritis
HIV Agents
HIV Seropositivity
HIV Seropositivity - drug therapy
HIV Seropositivity - epidemiology
HIV Seropositivity - physiopathology
HIV-1
Human immunodeficiency virus
Human viral diseases
Humans
Indinavir
Indinavir - adverse effects
Infectious diseases
Kidney Failure
Kidney Failure, Chronic - chemically induced
Kidney Failure, Chronic - epidemiology
Kidney Failure, Chronic - physiopathology
Kidneys
Male
male genital diseases
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Oligopeptides
Oligopeptides - adverse effects
Organophosphonates
Organophosphonates - adverse effects
Pyridines
Pyridines - adverse effects
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitors - adverse effects
Tenofovir
Urinary system involvement in other diseases. Miscellaneous
urologic
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
virus diseases
Publisher: Hagerstown, MD: Lippincott Williams & Wilkins
ID: ISSN: 0269-9370
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_754534620
title: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
format: Article
creator:
  • Mocroft, Amanda
  • Kirk, Ole
  • Reiss, Peter
  • de Wit, Stephane
  • Sedlacek, Dalibor
  • Beniowski, Marek
  • Gatell, Jose
  • Phillips, Anew N
  • Ledergerber, Bruno
  • Lundgren, Jens D
subjects:
  • 610 Medicine & health
  • Adenine
  • Adenine - adverse effects
  • Adenine - analogs & derivatives
  • Adult
  • AIDS/HIV
  • Anti
  • Anti-HIV Agents - adverse effects
  • Atazanavir Sulfate
  • Biological and medical sciences
  • Chronic
  • Clinic for Infectious Diseases
  • Disease Progression
  • Epidemiologic Methods
  • Female
  • Glomerular Filtration Rate
  • Glomerular Filtration Rate - drug effects
  • Glomerulonephritis
  • HIV Agents
  • HIV Seropositivity
  • HIV Seropositivity - drug therapy
  • HIV Seropositivity - epidemiology
  • HIV Seropositivity - physiopathology
  • HIV-1
  • Human immunodeficiency virus
  • Human viral diseases
  • Humans
  • Indinavir
  • Indinavir - adverse effects
  • Infectious diseases
  • Kidney Failure
  • Kidney Failure, Chronic - chemically induced
  • Kidney Failure, Chronic - epidemiology
  • Kidney Failure, Chronic - physiopathology
  • Kidneys
  • Male
  • male genital diseases
  • Medical sciences
  • Middle Aged
  • Nephrology. Urinary tract diseases
  • Nephropathies. Renovascular diseases. Renal failure
  • Oligopeptides
  • Oligopeptides - adverse effects
  • Organophosphonates
  • Organophosphonates - adverse effects
  • Pyridines
  • Pyridines - adverse effects
  • Reverse Transcriptase Inhibitors
  • Reverse Transcriptase Inhibitors - adverse effects
  • Tenofovir
  • Urinary system involvement in other diseases. Miscellaneous
  • urologic
  • Viral diseases
  • Viral diseases of the lymphoid tissue and the blood. Aids
  • virus diseases
ispartof: AIDS (London), 2010, Vol.24 (11), p.1667-1678
description: Objectives: Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD. Design: A cohort study including 6843 HIV-positive persons with at least three serum creatinine measurements and corresponding body weight measurements from 2004 onwards. Methods: CKD was defined as either confirmed (two measurements >= 3 months apart) estimated glomerular filtration rate (eGFR) of 60 ml/min per 1.73 m(2) or below for persons with baseline eGFR of above 60 ml/min per 1.73 m(2) or confirmed 25% decline in eGFR for persons with baseline eGFR of 60 ml/min per 1.73 m(2) or less, using the Cockcroft-Gault formula. Poisson regression was used to determine factors associated with CKD. Results: Two hundred and twenty-five (3.3%) persons progressed to CKD during 21 482 person-years follow-up, an incidence of 1.05 per 100 person-years follow-up [95% confidence interval (CI) 0.91-1.18]; median follow-up was 3.7 years (interquartile range 2.8-5.7). After adjustment for traditional factors associated with CKD and other confounding variables, increasing cumulative exposure to tenofovir [incidence rate ratio (IRR) per year 1.16, 95% CI 1.06-1.25, P
language: eng
source:
identifier: ISSN: 0269-9370
fulltext: no_fulltext
issn:
  • 0269-9370
  • 1473-5571
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.7194858
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_opena
recordidTN_cdi_proquest_miscellaneous_754534620
sourceformatXML
sourcesystemPC
sourcerecordid754534620
originalsourceidFETCH-LOGICAL-1633t-1c99d595628a9612fc16df9abdb27dc41e7582b3043353f287b31bc7a3b088960
addsrcrecordideNqFkktv1TAQhSMEopfCP0AoG8SGlPErttlVpXCvVAkhAUusie0UQ161k0r99_g-KKibu7DGSs58Myc5RfGSwBkBLd99Of9wBg0Q5hlVjOnWC_aoWBEuWSWEJI-LFdBaV5pJOCmepfQLAAQo9bQ4oSAoo8BWxc1lmkOPs3fldTf2Pi4dxrIN3RxxDuNQ5uLflvZnHIdgy9_BDf6udCF5TL7EweUzh-jnON6GiF3p4nJdLvldGMr15ns1jSnM4daXU-b5YU7Piyctdsm_ONTT4tvHy68X6-rq86fNxflVRWrG5opYrZ3QoqYKdU1oa0ntWo2Na6h0lhMvhaINA86YYC1VsmGksRJZkz3qGk6LzZ47Tn7AvKKZYnYa78yIwWQbs5mW_BQXIwG4t0iQOcRWZ7zTigpouNA8z8us9THW6IxSwjCnBdayba3SlNrsAKSXGqzmDbUeM-rNHjXF8WbxaTZ9SNZ3HQ5-XJKRggvGawrHldl4LWqyVfK90sYxpejb-_UImG1YTA6LeRiW3PbqMGBpeu_um_6mIwteHwSYLHZtxMGG9E_HIKv4Vvf-wXwb5l18copCd2yLH_vmAeP_dOxt3mv3gff_qbdm6PK96YLdwZOhHtC1hBmllTdcc2VQgDRWWssdt1RSDn8Akbj8BQ
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid733565610
display
typearticle
titleEstimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
creatorMocroft, Amanda ; Kirk, Ole ; Reiss, Peter ; de Wit, Stephane ; Sedlacek, Dalibor ; Beniowski, Marek ; Gatell, Jose ; Phillips, Anew N ; Ledergerber, Bruno ; Lundgren, Jens D
creatorcontribMocroft, Amanda ; Kirk, Ole ; Reiss, Peter ; de Wit, Stephane ; Sedlacek, Dalibor ; Beniowski, Marek ; Gatell, Jose ; Phillips, Anew N ; Ledergerber, Bruno ; Lundgren, Jens D ; EuroSIDA Study Group
descriptionObjectives: Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD. Design: A cohort study including 6843 HIV-positive persons with at least three serum creatinine measurements and corresponding body weight measurements from 2004 onwards. Methods: CKD was defined as either confirmed (two measurements >= 3 months apart) estimated glomerular filtration rate (eGFR) of 60 ml/min per 1.73 m(2) or below for persons with baseline eGFR of above 60 ml/min per 1.73 m(2) or confirmed 25% decline in eGFR for persons with baseline eGFR of 60 ml/min per 1.73 m(2) or less, using the Cockcroft-Gault formula. Poisson regression was used to determine factors associated with CKD. Results: Two hundred and twenty-five (3.3%) persons progressed to CKD during 21 482 person-years follow-up, an incidence of 1.05 per 100 person-years follow-up [95% confidence interval (CI) 0.91-1.18]; median follow-up was 3.7 years (interquartile range 2.8-5.7). After adjustment for traditional factors associated with CKD and other confounding variables, increasing cumulative exposure to tenofovir [incidence rate ratio (IRR) per year 1.16, 95% CI 1.06-1.25, P <0.0001), indinavir (IRR 1.12, 95% CI 1.06-1.18, P <0.0001), atazanavir (IRR 1.21, 95% CI 1.09-1.34, P=0.0003) and lopinavir/r (IRR 1.08, 95% CI 1.01-1.16, P=0.030) were associated with a significantly increased rate of CKD. Consistent results were observed in wide-ranging sensitivity analyses, although of marginal statistical significance for lopinavir/r. No other antiretroviral dugs were associated with increased incidence of CKD. Conclusion: In this nonrandomized large cohort, increasing exposure to tenofovir was associated with a higher incidence of CKD, as was true for indinavir and atazanavir, whereas the results for lopinavir/r were less clear. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
identifier
0ISSN: 0269-9370
1EISSN: 1473-5571
2DOI: 10.1097/QAD.0b013e328339fe53
3PMID: 20523203
languageeng
publisherHagerstown, MD: Lippincott Williams & Wilkins
subject610 Medicine & health ; Adenine ; Adenine - adverse effects ; Adenine - analogs & derivatives ; Adult ; AIDS/HIV ; Anti ; Anti-HIV Agents - adverse effects ; Atazanavir Sulfate ; Biological and medical sciences ; Chronic ; Clinic for Infectious Diseases ; Disease Progression ; Epidemiologic Methods ; Female ; Glomerular Filtration Rate ; Glomerular Filtration Rate - drug effects ; Glomerulonephritis ; HIV Agents ; HIV Seropositivity ; HIV Seropositivity - drug therapy ; HIV Seropositivity - epidemiology ; HIV Seropositivity - physiopathology ; HIV-1 ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Indinavir ; Indinavir - adverse effects ; Infectious diseases ; Kidney Failure ; Kidney Failure, Chronic - chemically induced ; Kidney Failure, Chronic - epidemiology ; Kidney Failure, Chronic - physiopathology ; Kidneys ; Male ; male genital diseases ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Oligopeptides ; Oligopeptides - adverse effects ; Organophosphonates ; Organophosphonates - adverse effects ; Pyridines ; Pyridines - adverse effects ; Reverse Transcriptase Inhibitors ; Reverse Transcriptase Inhibitors - adverse effects ; Tenofovir ; Urinary system involvement in other diseases. Miscellaneous ; urologic ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; virus diseases
ispartofAIDS (London), 2010, Vol.24 (11), p.1667-1678
rights
0info:eu-repo/semantics/restrictedAccess
12015 INIST-CNRS
lds50peer_reviewed
citedbyFETCH-LOGICAL-1633t-1c99d595628a9612fc16df9abdb27dc41e7582b3043353f287b31bc7a3b088960
citesFETCH-LOGICAL-1633t-1c99d595628a9612fc16df9abdb27dc41e7582b3043353f287b31bc7a3b088960
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23020343$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20523203$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Mocroft, Amanda
1Kirk, Ole
2Reiss, Peter
3de Wit, Stephane
4Sedlacek, Dalibor
5Beniowski, Marek
6Gatell, Jose
7Phillips, Anew N
8Ledergerber, Bruno
9Lundgren, Jens D
10EuroSIDA Study Group
title
0Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
1AIDS (London)
addtitleAIDS
descriptionObjectives: Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD. Design: A cohort study including 6843 HIV-positive persons with at least three serum creatinine measurements and corresponding body weight measurements from 2004 onwards. Methods: CKD was defined as either confirmed (two measurements >= 3 months apart) estimated glomerular filtration rate (eGFR) of 60 ml/min per 1.73 m(2) or below for persons with baseline eGFR of above 60 ml/min per 1.73 m(2) or confirmed 25% decline in eGFR for persons with baseline eGFR of 60 ml/min per 1.73 m(2) or less, using the Cockcroft-Gault formula. Poisson regression was used to determine factors associated with CKD. Results: Two hundred and twenty-five (3.3%) persons progressed to CKD during 21 482 person-years follow-up, an incidence of 1.05 per 100 person-years follow-up [95% confidence interval (CI) 0.91-1.18]; median follow-up was 3.7 years (interquartile range 2.8-5.7). After adjustment for traditional factors associated with CKD and other confounding variables, increasing cumulative exposure to tenofovir [incidence rate ratio (IRR) per year 1.16, 95% CI 1.06-1.25, P <0.0001), indinavir (IRR 1.12, 95% CI 1.06-1.18, P <0.0001), atazanavir (IRR 1.21, 95% CI 1.09-1.34, P=0.0003) and lopinavir/r (IRR 1.08, 95% CI 1.01-1.16, P=0.030) were associated with a significantly increased rate of CKD. Consistent results were observed in wide-ranging sensitivity analyses, although of marginal statistical significance for lopinavir/r. No other antiretroviral dugs were associated with increased incidence of CKD. Conclusion: In this nonrandomized large cohort, increasing exposure to tenofovir was associated with a higher incidence of CKD, as was true for indinavir and atazanavir, whereas the results for lopinavir/r were less clear. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
subject
0610 Medicine & health
1Adenine
2Adenine - adverse effects
3Adenine - analogs & derivatives
4Adult
5AIDS/HIV
6Anti
7Anti-HIV Agents - adverse effects
8Atazanavir Sulfate
9Biological and medical sciences
10Chronic
11Clinic for Infectious Diseases
12Disease Progression
13Epidemiologic Methods
14Female
15Glomerular Filtration Rate
16Glomerular Filtration Rate - drug effects
17Glomerulonephritis
18HIV Agents
19HIV Seropositivity
20HIV Seropositivity - drug therapy
21HIV Seropositivity - epidemiology
22HIV Seropositivity - physiopathology
23HIV-1
24Human immunodeficiency virus
25Human viral diseases
26Humans
27Indinavir
28Indinavir - adverse effects
29Infectious diseases
30Kidney Failure
31Kidney Failure, Chronic - chemically induced
32Kidney Failure, Chronic - epidemiology
33Kidney Failure, Chronic - physiopathology
34Kidneys
35Male
36male genital diseases
37Medical sciences
38Middle Aged
39Nephrology. Urinary tract diseases
40Nephropathies. Renovascular diseases. Renal failure
41Oligopeptides
42Oligopeptides - adverse effects
43Organophosphonates
44Organophosphonates - adverse effects
45Pyridines
46Pyridines - adverse effects
47Reverse Transcriptase Inhibitors
48Reverse Transcriptase Inhibitors - adverse effects
49Tenofovir
50Urinary system involvement in other diseases. Miscellaneous
51urologic
52Viral diseases
53Viral diseases of the lymphoid tissue and the blood. Aids
54virus diseases
issn
00269-9370
11473-5571
fulltextfalse
rsrctypearticle
creationdate2010
recordtypearticle
recordideNqFkktv1TAQhSMEopfCP0AoG8SGlPErttlVpXCvVAkhAUusie0UQ161k0r99_g-KKibu7DGSs58Myc5RfGSwBkBLd99Of9wBg0Q5hlVjOnWC_aoWBEuWSWEJI-LFdBaV5pJOCmepfQLAAQo9bQ4oSAoo8BWxc1lmkOPs3fldTf2Pi4dxrIN3RxxDuNQ5uLflvZnHIdgy9_BDf6udCF5TL7EweUzh-jnON6GiF3p4nJdLvldGMr15ns1jSnM4daXU-b5YU7Piyctdsm_ONTT4tvHy68X6-rq86fNxflVRWrG5opYrZ3QoqYKdU1oa0ntWo2Na6h0lhMvhaINA86YYC1VsmGksRJZkz3qGk6LzZ47Tn7AvKKZYnYa78yIwWQbs5mW_BQXIwG4t0iQOcRWZ7zTigpouNA8z8us9THW6IxSwjCnBdayba3SlNrsAKSXGqzmDbUeM-rNHjXF8WbxaTZ9SNZ3HQ5-XJKRggvGawrHldl4LWqyVfK90sYxpejb-_UImG1YTA6LeRiW3PbqMGBpeu_um_6mIwteHwSYLHZtxMGG9E_HIKv4Vvf-wXwb5l18copCd2yLH_vmAeP_dOxt3mv3gff_qbdm6PK96YLdwZOhHtC1hBmllTdcc2VQgDRWWssdt1RSDn8Akbj8BQ
startdate2010
enddate2010
creator
0Mocroft, Amanda
1Kirk, Ole
2Reiss, Peter
3de Wit, Stephane
4Sedlacek, Dalibor
5Beniowski, Marek
6Gatell, Jose
7Phillips, Anew N
8Ledergerber, Bruno
9Lundgren, Jens D
general
0Lippincott Williams & Wilkins
1Lippincott Wiliams & Wilkins
scope
05DI
15DJ
2QVL
3IQODW
4CGR
5CUY
6CVF
7ECM
8EIF
9NPM
10AAYXX
11CITATION
127X8
137T5
147U9
15H94
16CLFQK
sort
creationdate2010
titleEstimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
authorMocroft, Amanda ; Kirk, Ole ; Reiss, Peter ; de Wit, Stephane ; Sedlacek, Dalibor ; Beniowski, Marek ; Gatell, Jose ; Phillips, Anew N ; Ledergerber, Bruno ; Lundgren, Jens D
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1633t-1c99d595628a9612fc16df9abdb27dc41e7582b3043353f287b31bc7a3b088960
rsrctypearticles
prefilterarticles
languageeng
creationdate2010
topic
0610 Medicine & health
1Adenine
2Adenine - adverse effects
3Adenine - analogs & derivatives
4Adult
5AIDS/HIV
6Anti
7Anti-HIV Agents - adverse effects
8Atazanavir Sulfate
9Biological and medical sciences
10Chronic
11Clinic for Infectious Diseases
12Disease Progression
13Epidemiologic Methods
14Female
15Glomerular Filtration Rate
16Glomerular Filtration Rate - drug effects
17Glomerulonephritis
18HIV Agents
19HIV Seropositivity
20HIV Seropositivity - drug therapy
21HIV Seropositivity - epidemiology
22HIV Seropositivity - physiopathology
23HIV-1
24Human immunodeficiency virus
25Human viral diseases
26Humans
27Indinavir
28Indinavir - adverse effects
29Infectious diseases
30Kidney Failure
31Kidney Failure, Chronic - chemically induced
32Kidney Failure, Chronic - epidemiology
33Kidney Failure, Chronic - physiopathology
34Kidneys
35Male
36male genital diseases
37Medical sciences
38Middle Aged
39Nephrology. Urinary tract diseases
40Nephropathies. Renovascular diseases. Renal failure
41Oligopeptides
42Oligopeptides - adverse effects
43Organophosphonates
44Organophosphonates - adverse effects
45Pyridines
46Pyridines - adverse effects
47Reverse Transcriptase Inhibitors
48Reverse Transcriptase Inhibitors - adverse effects
49Tenofovir
50Urinary system involvement in other diseases. Miscellaneous
51urologic
52Viral diseases
53Viral diseases of the lymphoid tissue and the blood. Aids
54virus diseases
toplevelpeer_reviewed
creatorcontrib
0Mocroft, Amanda
1Kirk, Ole
2Reiss, Peter
3de Wit, Stephane
4Sedlacek, Dalibor
5Beniowski, Marek
6Gatell, Jose
7Phillips, Anew N
8Ledergerber, Bruno
9Lundgren, Jens D
10EuroSIDA Study Group
collection
0NARCIS
1NARCIS: Datasets
2NARCIS:Publications
3Pascal-Francis
4Medline
5MEDLINE
6MEDLINE (Ovid)
7MEDLINE
8MEDLINE
9PubMed
10CrossRef
11MEDLINE - Academic
12Immunology Abstracts
13Virology and AIDS Abstracts
14AIDS and Cancer Research Abstracts
15OpenAIRE
jtitleAIDS (London)
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Mocroft, Amanda
1Kirk, Ole
2Reiss, Peter
3de Wit, Stephane
4Sedlacek, Dalibor
5Beniowski, Marek
6Gatell, Jose
7Phillips, Anew N
8Ledergerber, Bruno
9Lundgren, Jens D
aucorpEuroSIDA Study Group
formatjournal
genrearticle
ristypeJOUR
atitleEstimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
jtitleAIDS (London)
addtitleAIDS
date2010
risdate2010
volume24
issue11
spage1667
epage1678
pages1667-1678
issn0269-9370
eissn1473-5571
abstractObjectives: Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD. Design: A cohort study including 6843 HIV-positive persons with at least three serum creatinine measurements and corresponding body weight measurements from 2004 onwards. Methods: CKD was defined as either confirmed (two measurements >= 3 months apart) estimated glomerular filtration rate (eGFR) of 60 ml/min per 1.73 m(2) or below for persons with baseline eGFR of above 60 ml/min per 1.73 m(2) or confirmed 25% decline in eGFR for persons with baseline eGFR of 60 ml/min per 1.73 m(2) or less, using the Cockcroft-Gault formula. Poisson regression was used to determine factors associated with CKD. Results: Two hundred and twenty-five (3.3%) persons progressed to CKD during 21 482 person-years follow-up, an incidence of 1.05 per 100 person-years follow-up [95% confidence interval (CI) 0.91-1.18]; median follow-up was 3.7 years (interquartile range 2.8-5.7). After adjustment for traditional factors associated with CKD and other confounding variables, increasing cumulative exposure to tenofovir [incidence rate ratio (IRR) per year 1.16, 95% CI 1.06-1.25, P <0.0001), indinavir (IRR 1.12, 95% CI 1.06-1.18, P <0.0001), atazanavir (IRR 1.21, 95% CI 1.09-1.34, P=0.0003) and lopinavir/r (IRR 1.08, 95% CI 1.01-1.16, P=0.030) were associated with a significantly increased rate of CKD. Consistent results were observed in wide-ranging sensitivity analyses, although of marginal statistical significance for lopinavir/r. No other antiretroviral dugs were associated with increased incidence of CKD. Conclusion: In this nonrandomized large cohort, increasing exposure to tenofovir was associated with a higher incidence of CKD, as was true for indinavir and atazanavir, whereas the results for lopinavir/r were less clear. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
copHagerstown, MD
pubLippincott Williams & Wilkins
pmid20523203
doi10.1097/QAD.0b013e328339fe53